Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer
Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer
复制标题
DOI：
10.1007/s00280-017-3289-6
复制
发表时间：
2017-05-01
影响因子：
3
通讯作者：
Shin, Jong Wook
中科院分区：
文献类型：
--
作者：
Jang, JoungSoon;Kim, Hoon-Kyo;Shin, Jong Wook
多西他赛/顺铂（DP）和吉西他滨/顺铂（GP）是晚期非小细胞肺癌（NSCLC）的标准治疗方案。尽管有效性强，但与GP相比，传统的1天DP被认为具有更大的毒性。人们越来越关注DP的两周分次给药以降低其毒性。假设在老年或体力状态差（PS）患者中，一线双周DP与GP一样安全。
Docetaxel/cisplatin (DP) and gemcitabine/cisplatin (GP) are standard treatment regimens for advanced non-small cell lung cancer (NSCLC). In spite of potent efficacy, the conventional 1-day DP is regarded as having more toxicity as compared with GP. There is increasing interest in a biweekly split administration of DP to reduce its toxicity. Hypothesis was that first-line biweekly DP is as safe as GP in the elderly or poor performance status (PS) patients.Chemotherapy-na < ve patients with advanced NSCLC (IIIB/IV) who were elderly (65